v3.26.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2026
Dec. 31, 2025
CURRENT ASSETS    
Cash and cash equivalents $ 11,422 $ 2,169
Restricted Cash 10 240
Clinical trial services asset [1] 366 0
Trade receivables, net of credit losses of $234 and $192, respectively 5,664 6,138
Prepaid expenses and other current assets 1,844 1,528
Inventories 6,251 5,732
Total current assets 25,557 15,807
LONG-TERM ASSETS    
Restricted cash and other long-term assets 436 209
Clinical trial services asset [1] 609 0
Operating lease right-of-use assets 1,491 1,544
Property and equipment, net 571 585
Goodwill 4,755 4,755
Total long-term assets 7,862 7,093
Total assets 33,419 22,900
CURRENT LIABILITIES    
Trade payables 6,376 5,590
Employees and payroll accruals 1,285 1,442
Deferred revenues 966 920
Convertible promissory note [2] 0 2,803
Current maturities of operating leases liability 425 425
Other current liabilities 1,583 859
Total current liabilities 10,635 12,039
LONG-TERM LIABILITIES    
Convertible promissory notes, net [3] 7,276 0
Warrant liabilities [4] 6,842 0
Deferred revenues 1,208 1,233
Non-current operating leases liability 1,113 1,159
Other long-term liabilities 54 61
Total long-term liabilities 16,493 2,453
Total liabilities 27,128 14,492
COMMITMENTS AND CONTINGENT LIABILITIES
Shareholders’ equity:    
Share capitalOrdinary share Authorized: 100,000,000 shares at March 31, 2026 and 75,000,000 December 31, 2025; Issued: 2,826,473 and 1,572,319 shares at March 31, 2026 and December 31, 2025, respectively; Outstanding: 2,778,585 and 1,524,431 shares as of March 31, 2026 and December 31, 2025 respectively [5] 9,418 9,418
Additional paid-in capital 295,608 286,932
Treasury Shares at cost, 47,888 ordinary shares at March 31, 2026 and December 31, 2025 (3,203) (3,203)
Accumulated deficit (295,532) (284,739)
Total shareholders' equity 6,291 8,408
Total liabilities and shareholders' equity $ 33,419 $ 22,900
[1] Balance relates entirely to a related party arrangement with Oramed Pharmaceuticals Inc.
[2] Represents amounts due to Oramed Pharmaceuticals Inc. as of December 31, 2025. Oramed became a related party upon completion of the March 2026 transaction.
[3] Includes balances attributable to Oramed Pharmaceuticals Inc., a related party, of $6,542 as of March 31, 2026.
[4] Includes balances attributable to Oramed Pharmaceuticals Inc., a related party, of $6,557 as of March 31, 2026.
[5] Reflects the one-for-twelve reverse share split that became effective on February 24, 2026. See Note 8a to the condensed consolidated financial statements.